Maze Therapeutics (NASDAQ:MAZE) Insider Sells 3,191 Shares of Stock

Key Points

• Insider sale: Atul Dandekar sold 3,191 Maze Therapeutics shares for approximately $84,466, reducing his direct position by 8.23%. The sale was made to cover tax withholding related to vested equity awards.
• Stock performance and outlook: MAZE shares rose 1.3% to $26.21, but remain below their 50-day and 200-day moving averages. The company reported a quarterly loss of $0.76 per share, with analysts forecasting a $2.72 full-year loss.
• Analyst sentiment remains positive: Despite some sell ratings and recent insider selling, the consensus rating is “Buy,” with an average price target of $66.00; TD Cowen upgraded the stock to “strong buy,” while BTIG maintained a “buy” rating with a $46 target.

Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) insider Atul Dandekar sold 3,191 shares of the stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $26.47, for a total value of $84,465.77. Following the completion of the transaction, the insider directly owned 35,559 shares of the company's stock, valued at $941,246.73. This represents a 8.23% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Atul Dandekar also recently made the following trade(s):

• On Thursday, September 3rd, Atul Dandekar sold 3,243 shares of Maze Therapeutics stock. The shares were sold at an average price of $26.01, for a total value of $84,350.43.
• On Friday, August 28th, Atul Dandekar sold 7,500 shares of Maze Therapeutics stock. The stock was sold at an average price of $27.58, for a total value of $206,850.00.
• On Wednesday, July 29th, Atul Dandekar sold 7,500 shares of Maze Therapeutics stock. The shares were sold at an average price of $27.34, for a total value of $205,050.00.
• On Monday, June 29th, Atul Dandekar sold 7,500 shares of Maze Therapeutics stock. The shares were sold at an average price of $28.02, for a total value of $210,150.00.

Maze Therapeutics Stock Up 1.3%

Shares of MAZE stock traded up $0.34 during mid-day trading on Friday, reaching $26.21. 273,266 shares of the company were exchanged, compared to its average volume of 637,671. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.31 and a current ratio of 18.31. The business's 50 day simple moving average is $28.74 and its 200 day simple moving average is $31.20. The company has a market capitalization of $1.46 billion, a P/E ratio of -10.40 and a beta of 2.17. Maze Therapeutics, Inc. has a fifty-two week low of $14.27 and a fifty-two week high of $53.65.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.76). Research analysts predict that Maze Therapeutics, Inc. will post -2.72 earnings per share for the current year.

Analysts Set New Price Targets

MAZE has been the topic of several research analyst reports. BTIG Research reaffirmed a "buy" rating and set a $46.00 price target on shares of Maze Therapeutics in a research report on Wednesday, August 12th. Wall Street Zen cut Maze Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, August 15th. TD Cowen raised Maze Therapeutics to a "strong-buy" rating in a report on Monday, August 24th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Maze Therapeutics in a research report on Wednesday, June 24th. Three analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Maze Therapeutics presently has a consensus rating of "Buy" and an average price target of $66.00.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Royal Bank of Canada boosted its holdings in shares of Maze Therapeutics by 128.3% in the 4th quarter. Royal Bank of Canada now owns 646 shares of the company's stock valued at $27,000 after buying an additional 363 shares during the period. Ameritas Investment Partners Inc. raised its stake in Maze Therapeutics by 82.6% during the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company's stock worth $42,000 after acquiring an additional 738 shares during the period. California State Teachers Retirement System lifted its holdings in Maze Therapeutics by 138.0% in the fourth quarter. California State Teachers Retirement System now owns 1,321 shares of the company's stock worth $55,000 after acquiring an additional 766 shares during the last quarter. Police & Firemen s Retirement System of New Jersey boosted its stake in Maze Therapeutics by 18.5% in the fourth quarter. Police & Firemen s Retirement System of New Jersey now owns 5,961 shares of the company's stock valued at $247,000 after acquiring an additional 931 shares during the period. Finally, Legal & General Group Plc boosted its stake in Maze Therapeutics by 23.0% in the third quarter. Legal & General Group Plc now owns 5,219 shares of the company's stock valued at $135,000 after acquiring an additional 977 shares during the period.

Trending Headlines about Maze Therapeutics

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: Analyst sentiment remains broadly constructive. TD Cowen upgraded MAZE to “strong buy,” BTIG reiterated a “buy” rating with a $46 price target, and the consensus rating is “buy” with an average target of $66.00. Maze Therapeutics insider trading and analyst coverage
• Neutral Sentiment: Institutional ownership activity included purchases or position increases by Royal Bank of Canada, Russell Investments Group and other firms. These holdings are relatively small, however, and are unlikely to be a major near-term price driver.
• Neutral Sentiment: Maze’s CEO Jason Coloma, CMO Harold Bernstein and other insiders sold shares between September 1 and September 3. Combined reported sales totaled roughly $2.4 million, but the filings said the transactions were made to cover tax obligations from equity vesting; Bernstein’s September 1 sale was also conducted under a pre-arranged Rule 10b5-1 plan. SEC insider trading filing
• Negative Sentiment: The scale and repetition of insider selling may weigh on investor sentiment, particularly as the CEO reduced his directly held shares substantially. MAZE has also been trading below its 50-day and 200-day moving averages, signaling continued technical weakness. The company remains loss-making, with quarterly EPS of negative $0.76 and analysts expecting approximately negative $2.72 EPS for the year.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc NASDAQ: MAZE is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze's approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source